Quarterly ResultJul 30, 2026, 08:38 AM
Disc Medicine Q2 Net Loss $59.5M; $717.7M Cash & Securities
AI Summary
Disc Medicine, Inc. reported a net loss of $59.5 million for the second quarter of 2026, contributing to a year-to-date net loss of $123.0 million. The clinical-stage biopharmaceutical company continues to incur significant research and development expenses, totaling $46.9 million for the quarter. As of June 30, 2026, the company maintained a strong liquidity position with $717.7 million in cash, cash equivalents, and marketable securities, which is projected to fund operations for at least the next twelve months.
Key Highlights
- Reported a net loss of $59.5 million for the second quarter of 2026.
- Year-to-date net loss for 2026 was $123.0 million.
- Research and development expenses were $46.9 million in Q2 2026.
- Selling, general and administrative expenses were $18.1 million in Q2 2026.
- Cash, cash equivalents, and marketable securities totaled $717.7 million as of June 30, 2026.
- Accumulated deficit reached $633.2 million as of June 30, 2026.
- Net cash used in operating activities was $106.4 million for the six months ended June 30, 2026.
- Existing capital is expected to fund operations for at least twelve months.
Price Impact
More from IRON